

Su Jin Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3399492/publications.pdf>

Version: 2024-02-01

203
papers

5,101
citations

126907

33
h-index

123424

61
g-index

203
all docs

203
docs citations

203
times ranked

9480
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. <i>Nature Medicine</i> , 2018, 24, 1449-1458.	30.7	1,071
2	Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 115-122.	1.5	194
3	Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors. <i>Journal of Thoracic Oncology</i> , 2013, 8, 185-191.	1.1	163
4	Reversal of Vascular ¹⁸ F-FDG Uptake with Plasma High-Density Lipoprotein Elevation by Atherogenic Risk Reduction. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1277-1282.	5.0	108
5	Identification of ROS1 rearrangement in gastric adenocarcinoma. <i>Cancer</i> , 2013, 119, 1627-1635.	4.1	108
6	The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. <i>Journal of Cancer</i> , 2016, 7, 484-489.	2.5	106
7	A Machine-Learning Approach Using PET-Based Radiomics to Predict the Histological Subtypes of Lung Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 956-960.	1.3	101
8	Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. <i>Cancer Research and Treatment</i> , 2011, 43, 89-95.	3.0	79
9	c-MET Overexpression in Colorectal Cancer: A Poor Prognostic Factor for Survival. <i>Clinical Colorectal Cancer</i> , 2018, 17, 165-169.	2.3	71
10	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	3.7	70
11	Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. <i>International Journal of Cancer</i> , 2009, 124, 1457-1462.	5.1	69
12	Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2019, 14, e0210730.	2.5	64
13	Oxidized Low-Density Lipoprotein Stimulates Macrophage ¹⁸ F-FDG Uptake via Hypoxia-Inducible Factor-1 α Activation Through Nox2-Dependent Reactive Oxygen Species Generation. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1699-1705.	5.0	63
14	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	2.6	58
15	Gastrointestinal malignancies harbor actionable MET exon 14 deletions. <i>Oncotarget</i> , 2015, 6, 28211-28222.	1.8	57
16	Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters. <i>Lung Cancer</i> , 2017, 104, 31-37.	2.0	54
17	NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line. <i>Oncotarget</i> , 2015, 6, 39028-39035.	1.8	53
18	Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 229-235.	2.3	49

#	ARTICLE	IF	CITATIONS
19	Prognostic Value of Volume-Based ¹⁸ F-Fluorodeoxyglucose PET/CT Parameters in Patients with Clinically Node-Negative Oral Tongue Squamous Cell Carcinoma. Korean Journal of Radiology, 2012, 13, 752.	3.4	48
20	Patient-derived cell models as preclinical tools for genome-directed targeted therapy. Oncotarget, 2015, 6, 25619-25630.	1.8	48
21	Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01). Cancer, 2017, 123, 1958-1964.	4.1	44
22	Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Investigational New Drugs, 2019, 37, 567-572.	2.6	44
23	Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2013, 8, 250-253.	1.1	43
24	Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer. Cancer Imaging, 2015, 15, 21.	2.8	43
25	A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Research, 2013, 33, 5179-86.	1.1	42
26	Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Nuklearmedizin - Nuclear Medicine, 2014, 53, 89-94.	0.7	41
27	Localization of Dystonic Muscles with 18F-FDG PET/CT in Idiopathic Cervical Dystonia. Journal of Nuclear Medicine, 2007, 48, 1790-1795.	5.0	40
28	A multi-center, open-label, randomized phase III trial of first-line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. Journal of Geriatric Oncology, 2017, 8, 170-175.	1.0	39
29	Decreased Metabolism in the Cerebral Cortex in Early-Stage Huntington's Disease: A Possible		

#	ARTICLE	IF	CITATIONS
37	The Influence of Metastatic Lymph Node Ratio on the Treatment Outcomes in the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Trial: A Phase III Trial. <i>Journal of Gastric Cancer</i> , 2016, 16, 105.	2.5	34
38	Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience. <i>The Korean Journal of Hepatology</i> , 2012, 18, 48.	1.5	34
39	Usefulness of 18F-fluoride PET/CT in Breast Cancer Patients with Osteosclerotic Bone Metastases. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 27-35.	1.0	33
40	Symptomatic late-onset sialadenitis after radioiodine therapy in thyroid cancer. <i>Annals of Nuclear Medicine</i> , 2013, 27, 386-391.	2.2	33
41	Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients. <i>Investigational New Drugs</i> , 2013, 31, 1580-1586.	2.6	33
42	Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 1217-1225.	2.3	32
43	Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 255-262.	2.3	31
44	The Correlations Between MRI Perfusion, Diffusion Parameters, and 18F-FDG PET Metabolic Parameters in Primary Head-and-Neck Cancer. <i>Medicine (United States)</i> , 2015, 94, e2141.	1.0	31
45	DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. <i>Annals of Hematology</i> , 2014, 93, 99-105.	1.8	29
46	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. <i>Medical Oncology</i> , 2009, 26, 45-48.	2.5	28
47	Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma. <i>Clinical Sarcoma Research</i> , 2014, 4, 13.	2.3	28
48	Prognostic Significance of EDIL3 Expression and Correlation with Mesenchymal Phenotype and Microvessel Density in Lung Adenocarcinoma. <i>Scientific Reports</i> , 2017, 7, 8649.	3.3	28
49	Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <i>Cancer Research and Treatment</i> , 2018, 50, 488-494.	3.0	28
50	Atypical basal ganglia germinoma presenting as cerebral hemiatrophy: diagnosis and follow-up with 11C-methionine positron emission tomography. <i>Child's Nervous System</i> , 2009, 25, 29-37.	1.1	27
51	Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 743-751.	2.3	27
52	ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. <i>Lung Cancer</i> , 2012, 76, 253-254.	2.0	26
53	Gastric cancer (GC) patients with hedgehog pathway activation: PTCH1 and GLI2 as independent prognostic factors. <i>Targeted Oncology</i> , 2013, 8, 271-280.	3.6	25
54	Circulating Tumor Cells are Predictive of Poor Response to Chemotherapy in Metastatic gastric cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 382-386.	1.8	25

#	ARTICLE	IF	CITATIONS
55	Intratumoural heterogeneity measured using FDG PET and MRI is associated with tumourâ€‘stroma ratio and clinical outcome in head and neck squamous cell carcinoma. <i>Clinical Radiology</i> , 2017, 72, 482-489.	1.1	25
56	Retrospective multicenter study on the development of peripheral lymphocytosis following secondâ€‘line dasatinib therapy for chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2011, 86, 346-350.	4.1	24
57	PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data. <i>Lung Cancer</i> , 2019, 129, 41-47.	2.0	24
58	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	1.4	23
59	Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. <i>BMC Cancer</i> , 2015, 15, 693.	2.6	23
60	Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea. <i>Breast</i> , 2015, 24, 213-217.	2.2	23
61	MerTK is a novel therapeutic target in gastric cancer. <i>Oncotarget</i> , 2017, 8, 96656-96667.	1.8	23
62	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , 2017, 49, 350-357.	3.0	23
63	Resting cerebral glucose metabolism and perfusion patterns in women with posttraumatic stress disorder related to sexual assault. <i>Psychiatry Research - Neuroimaging</i> , 2012, 201, 214-217.	1.8	22
64	Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 782-790.	2.6	22
65	Unique perception of clinical trials by Korean cancer patients. <i>BMC Cancer</i> , 2012, 12, 594.	2.6	21
66	Direct analysis of aberrant glycosylation on haptoglobin in patients with gastric cancer. <i>Oncotarget</i> , 2017, 8, 11094-11104.	1.8	21
67	Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. <i>Cancer</i> , 2009, 115, 1518-1530.	4.1	20
68	Extraosseous osteosarcoma: Single institutional experience in Korea. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2010, 6, 126-129.	1.1	20
69	Prognostic significance of lactate dehydrogenase B according to histologic type of non-small-cell lung cancer and its association with serum lactate dehydrogenase. <i>Pathology Research and Practice</i> , 2017, 213, 1134-1138.	2.3	20
70	Prognostic value of preoperative total psoas muscle area on long-term outcome in surgically treated oesophageal cancer patients. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, 13-19.	1.1	20
71	The implication of FLT3 amplification for FLT targeted therapeutics in solid tumors. <i>Oncotarget</i> , 2017, 8, 3237-3245.	1.8	20
72	Neogaroooligosaccharides prevent septic shock by modulating A20-and cyclooxygenase-2-mediated interleukin-10 secretion in a septic-shock mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 998-1004.	2.1	19

#	ARTICLE	IF	CITATIONS
73	Clinical implication of Time To Brain Metastasis (TTBM) according to breast cancer subtypes. SpringerPlus, 2013, 2, 136.	1.2	18
74	Salivary gland scintigraphy in Sjögren's syndrome. Nuklearmedizin - NuclearMedicine, 2014, 53, 139-145.	0.7	18
75	Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?. Cancer Chemotherapy and Pharmacology, 2014, 73, 1063-1070.	2.3	18
76	Correlation Between F-18 Fluorodeoxyglucose Positron Emission Tomography Metabolic Parameters and Dynamic Contrast-Enhanced MRI-Derived Perfusion Data in Patients with Invasive Ductal Breast Carcinoma. Annals of Surgical Oncology, 2015, 22, 3866-3872.	1.5	18
77	The Highest Metabolic Activity on FDG PET Is Associated With Overall Survival in Limited-Stage Small-Cell Lung Cancer. Medicine (United States), 2016, 95, e2772.	1.0	18
78	Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 61-67.	1.1	18
79	Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. BMC Urology, 2018, 18, 68.	1.4	18
80	Homeostasis and regulation of autoreactive B cells. Cellular and Molecular Immunology, 2020, 17, 561-569.	10.5	18
81	Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. Medicine (United States), 2015, 94, e2063.	1.0	17
82	Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. BMC Cancer, 2015, 15, 530.	2.6	17
83	Genomic Profiling of Metastatic Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients in the Personalized-Medicine Era. Journal of Cancer, 2016, 7, 1044-1048.	2.5	17
84	Postoperative change of the psoas muscle area as a predictor of survival in surgically treated esophageal cancer patients. Journal of Thoracic Disease, 2017, 9, 355-361.	1.4	17
85	Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer. Clinical Colorectal Cancer, 2018, 17, 140-146.	2.3	17
86	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. Translational Oncology, 2016, 9, 557-564.	3.7	16
87	The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET-CT in surgically treated esophageal squamous cell carcinoma. Annals of Nuclear Medicine, 2016, 30, 81-88.	2.2	15
88	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. Apmis, 2017, 125, 223-229.	2.0	15
89	PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA. Oncotarget, 2015, 6, 40026-40035.	1.8	15
90	Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget, 2016, 7, 24088-24096.	1.8	15

#	ARTICLE	IF	CITATIONS
91	Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 1540-1547.	2.6	14
92	Clinical significance of post-treatment 18F-fluorodeoxyglucose uptake in cervical lymph nodes in patients with diffuse large B-cell lymphoma. <i>European Radiology</i> , 2016, 26, 4632-4639.	4.5	14
93	A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. <i>BMC Urology</i> , 2016, 16, 46.	1.4	14
94	Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma. <i>Translational Oncology</i> , 2016, 9, 466-471.	3.7	13
95	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e3.	2.2	13
96	Apparent Relative Hypermetabolism of Selective Brain Areas in Huntington Disease and Importance of Reference Region for Analysis. <i>Clinical Nuclear Medicine</i> , 2012, 37, 663-668.	1.3	12
97	Adjuvant Chemotherapy with or without Concurrent Radiotherapy for Patients with Stage IB Gastric Cancer: a Subgroup Analysis of the Adjuvant Chemoradiotherapy in Stomach Tumors (ARTIST) Phase III Trial. <i>Journal of Gastric Cancer</i> , 2018, 18, 348.	2.5	12
98	Necessity of adjuvant concurrent chemo-radiotherapy in D2-resected LN-positive gastric cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 306-312.	0.6	12
99	Skeletal muscle mass at C3 may not be a strong predictor for skeletal muscle mass at L3 in sarcopenic patients with head and neck cancer. <i>PLoS ONE</i> , 2021, 16, e0254844.	2.5	12
100	Modified Transobturator Tape (Canal Transobturator Tape) Surgery for Female Stress Urinary Incontinence. <i>Journal of Urology</i> , 2009, 181, 2616-2621.	0.4	11
101	Significance of Salivary Gland Radioiodine Retention on Post-ablation 131I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 203-211.	1.0	11
102	Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin). <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1231-1237.	2.5	11
103	Prognostic utility of FDG PET/CT and bone scintigraphy in breast cancer patients with bone-only metastasis. <i>Medicine (United States)</i> , 2017, 96, e8985.	1.0	11
104	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. <i>Journal of Immunotherapy</i> , 2019, 42, 279-283.	2.4	11
105	Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2825.	4.1	11
106	Associations Between PET Textural Features and GLUT1 Expression, and the Prognostic Significance of Textural Features in Lung Adenocarcinoma. <i>Anticancer Research</i> , 2018, 38, 1067-1071.	1.1	11
107	The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 153-161.	3.0	11
108	The usefulness and accuracy of sentinel lymph node biopsy using single photon emission computed tomography/computed tomography with 99mTc phytate to detect locoregional lymph node metastases in patients with papillary thyroid carcinoma. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 84, 195.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. <i>BMC Cancer</i> , 2015, 15, 747.	2.6	10
110	Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2015, 15, e287-e292.	2.4	10
111	BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells. <i>Translational Oncology</i> , 2016, 9, 197-202.	3.7	10
112	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016, 6, 8.	2.3	10
113	Myostatin inhibitor YK11 as a preventative health supplement for bacterial sepsis. <i>Biochemical and Biophysical Research Communications</i> , 2021, 543, 1-7.	2.1	10
114	A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. <i>Cancer Research and Treatment</i> , 2019, 51, 718-726.	3.0	10
115	Variation in FDG uptake on PET in patients with radiation-induced pelvic insufficiency fractures: a review of 10 cases. <i>Annals of Nuclear Medicine</i> , 2009, 23, 511-516.	2.2	9
116	Analysis of Prognostic Factors of Pediatric-Type Sarcomas in Adult Patients. <i>Oncology</i> , 2011, 80, 21-28.	1.9	9
117	Primary Malignant Fibrous Histiocytoma in Mediastinum: Imaging with 18F-FDG PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2012, 46, 304-307.	1.0	9
118	Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. <i>Journal of Clinical Neuroscience</i> , 2013, 20, 938-942.	1.5	9
119	Inflammatory Pseudotumor in the Mediastinum: Imaging with ¹⁸ F-Fluorodeoxyglucose PET/CT. <i>Korean Journal of Radiology</i> , 2013, 14, 673.	3.4	9
120	Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 40-45.	1.3	9
121	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	2.6	9
122	Myocardial perfusion defects and coronary risk factors in symptomatic and asymptomatic elderly women. <i>International Journal of Cardiovascular Imaging</i> , 2008, 24, 277-281.	1.5	8
123	Ultrashort-acting insulin may improve on 18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus. <i>Nuclear Medicine Communications</i> , 2013, 34, 527-532.	1.1	8
124	Carotid Artery FDG Uptake May Serve as a Biomarker for Cardiovascular Risk Stratification in Asymptomatic Adults. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 196-202.	1.0	8
125	The Correlation Between Serum Chemokines and Clinical Outcome in Patients with Advanced Biliary Tract Cancer. <i>Translational Oncology</i> , 2018, 11, 353-357.	3.7	8
126	Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. <i>Translational Oncology</i> , 2019, 12, 597-601.	3.7	8

#	ARTICLE	IF	CITATIONS
127	Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization. <i>Anticancer Research</i> , 2016, 36, 5975-5980.	1.1	8
128	Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. <i>Cancer Research and Treatment</i> , 2019, 51, 876-885.	3.0	8
129	Neutrophil Counts Could Predict the Response to Immunosuppressive Treatment with Antithymocyte Globulin and Cyclosporine in the Patients with Severe Aplastic Anemia. <i>Blood</i> , 2008, 112, 4109-4109.	1.4	8
130	A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer. <i>BMC Urology</i> , 2017, 17, 63.	1.4	7
131	Clinical usefulness of F-18 FDG PET in lymphoepithelioma-like gastric carcinoma. <i>European Journal of Radiology</i> , 2017, 94, 160-166.	2.6	7
132	The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer. <i>Journal of Cancer</i> , 2019, 10, 1611-1615.	2.5	7
133	Risk Factors for Indeterminate Response After Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2019, 44, 714-718.	1.3	7
134	¹⁸ F-fluorodeoxyglucose positron emission tomography is correlated with the pathological necrosis and decreased microvessel density in lung adenocarcinomas. <i>Annals of Nuclear Medicine</i> , 2019, 33, 93-102.	2.2	7
135	Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	1.3	7
136	Postnatal regulation of B-1a cell development and survival by the CIC-PER2-BHLHE41 axis. <i>Cell Reports</i> , 2022, 38, 110386.	6.4	7
137	Comparison of Uptake Characteristics and Prognostic Value of ²⁰¹ Tl and ¹⁸ F-FDG in Esophageal Cancer. <i>World Journal of Surgery</i> , 2008, 32, 69-75.	1.6	6
138	Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL). <i>International Journal of Hematology</i> , 2013, 97, 388-396.	1.6	6
139	Isolated Splenic Metastasis of Ovarian Cancer Detected With ¹⁸ F-FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, 349-351.	1.3	6
140	Physiologic Facial Muscle Uptake on ¹⁸ F-FDG PET/CT by Chewing-Like Habitual Movement in Patient With Sjögren Syndrome. <i>Clinical Nuclear Medicine</i> , 2015, 40, 268-269.	1.3	6
141	Radiolabeled Anti-Adenosine Triphosphate Synthase Monoclonal Antibody as a Theragnostic Agent Targeting Angiogenesis. <i>Molecular Imaging</i> , 2017, 16, 153601211773739.	1.4	6
142	Pemetrexed Monotherapy as Salvage Treatment in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy: A Phase II Single-arm Prospective Trial. <i>Journal of Cancer</i> , 2018, 9, 2910-2915.	2.5	6
143	Intratumoral heterogeneity as measured using the tumor-stroma ratio and PET texture analyses in females with lung adenocarcinomas differs from that of males with lung adenocarcinomas or squamous cell carcinomas. <i>Medicine (United States)</i> , 2019, 98, e14876.	1.0	6
144	Salvage S-1 monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy. <i>Medical Oncology</i> , 2011, 28, 291-294.	2.5	5

#	ARTICLE	IF	CITATIONS
145	The Utility of Segmental Analysis in Cardiac I-123 MIBG SPECT in Parkinson's Disease. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 298-302.	1.0	5
146	Comparison of Diagnostic Performance Between Visual and Quantitative Assessment of Bone Scintigraphy Results in Patients With Painful Temporomandibular Disorder. <i>Medicine (United States)</i> , 2016, 95, e2485.	1.0	5
147	Troglitazone Stimulates Cancer Cell Uptake of ¹⁸ F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction. <i>Journal of Nuclear Medicine</i> , 2016, 57, 129-135.	5.0	5
148	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma. <i>Journal of Cancer</i> , 2019, 10, 3140-3144.	2.5	5
149	A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. <i>BMC Urology</i> , 2019, 19, 30.	1.4	5
150	Comparison of bone single-photon emission computed tomography (SPECT)/CT and bone scintigraphy in assessing knee joints. <i>BMC Medical Imaging</i> , 2021, 21, 60.	2.7	5
151	Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated. <i>Scientific Reports</i> , 2021, 11, 12297.	3.3	5
152	Incidental Multiple Focal Uptakes of Tc-99m MDP in Both Lungs Without Lung Parenchymal Abnormality. <i>Clinical Nuclear Medicine</i> , 2011, 36, 221-223.	1.3	4
153	Clinical presentation of carcinoma of unknown primary: 14 years of experience. <i>Tumor Biology</i> , 2011, 32, 45-51.	1.8	4
154	PIK3CA Mutations in Hepatocellular Carcinoma in Korea. <i>Yonsei Medical Journal</i> , 2013, 54, 883.	2.2	4
155	Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs. <i>Lung Cancer</i> , 2015, 90, 261-266.	2.0	4
156	Serosal Cavities Contain Two Populations of Innate-like integrin ^{hi} CD4 ⁺ T Cells, Integrin ^{hi} CD4 ⁺ CD27 ⁺ and Integrin ^{hi} CD4 ⁺ CD27 ⁻ Cells. <i>Immune Network</i> , 2017, 17, 392.	3.6	4
157	Clinical benefit and residual kidney function of en bloc nephrectomy for perirenal retroperitoneal sarcoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e465-e471.	1.1	4
158	The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 225-231.	2.0	4
159	Clinicopathologic parameters associated with the FDG-avidity in staging of early gastric cancer using 18F-FDG PET. <i>Medicine (United States)</i> , 2019, 98, e16690.	1.0	4
160	Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer. <i>Scientific Reports</i> , 2020, 10, 4713.	3.3	4
161	IOX1 activity as sepsis therapy and an antibiotic against multidrug-resistant bacteria. <i>Scientific Reports</i> , 2021, 11, 2942.	3.3	4
162	Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study. <i>Cancer Research and Treatment</i> , 2019, 51, 1269-1274.	3.0	4

#	ARTICLE	IF	CITATIONS
163	Development of Infection Control Guideline for Postpartum Care Centers. Korean Journal of Nosocomial Infection Control, 2013, 18, 57.	1.5	3
164	Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists. Expert Opinion on Emerging Drugs, 2017, 22, 191-200.	2.4	3
165	Phase II trial of nintedanib in patients with recurrent or metastatic salivary gland cancer: A multicenter phase II study.. Journal of Clinical Oncology, 2016, 34, 6090-6090.	1.6	3
166	Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2019, 37, 3023-3023.	1.6	3
167	Enhanced Expression and Functional Characterization of the Recombinant Putative Lysozyme-PMAP36 Fusion Protein. Molecules and Cells, 2019, 42, 262-269.	2.6	3
168	Incidental Focal Uptake in Oropharynx Due to Lingual Thyroid on Diagnostic 131I Whole-Body Scan After Total Thyroidectomy. Clinical Nuclear Medicine, 2013, 38, 646-648.	1.3	2
169	The Clinical Impacts of Apparent Embolic Event and the Predictors of In-Hospital Mortality in Patients with Infective Endocarditis. Journal of Korean Medical Science, 2014, 29, 1646.	2.5	2
170	Single Pulmonary Langerhans Cell Histiocytosis Mimicking Metastasis in Lung Cancer: Imaging with 18F-FDG PET/CT. Nuclear Medicine and Molecular Imaging, 2015, 49, 243-245.	1.0	2
171	A Case of Radioactive Iodine Uptake Found in Artificial Eye. Clinical Nuclear Medicine, 2019, 44, 317-318.	1.3	2
172	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. Journal of Clinical Oncology, 2015, 33, 2522-2522.	1.6	2
173	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients: Integrative pathologic-genomic analysis and the final results.. Journal of Clinical Oncology, 2019, 37, 3104-3104.	1.6	2
174	Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. Anticancer Research, 2014, 34, 6585-91.	1.1	2
175	Clinical Significance of Diffuse 18F-FDG Uptake in Residual Thyroid Gland after Unilateral Thyroid Lobectomy. Nuclear Medicine and Molecular Imaging, 2011, 45, 197-202.	1.0	1
176	POEMS Syndrome Presenting with Acute Demyelinating Polyneuropathy: Increased Terminal Latency Indices and Uniform Demyelination. Internal Medicine, 2013, 52, 1513-1516.	0.7	1
177	An investigation of the role of gene copy number variations in sorafenib sensitivity in metastatic hepatocellular carcinoma patients. Journal of Cancer, 2017, 8, 730-736.	2.5	1
178	Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on 18F-FP-CIT PET/CT Image. Clinical Nuclear Medicine, 2019, 44, e168-e169.	1.3	1
179	Multicenter Retrospective Study on the Development of Peripheral Lymphocytosis During Second-Line Dasatinib Therapy for Chronic Myeloid Leukemia. Blood, 2010, 116, 2275-2275.	1.4	1
180	First-in-human phase I trial of anti-hepatocyte growth factor (HGF) antibody (YYB101) in refractory solid tumor patients.. Journal of Clinical Oncology, 2018, 36, e14501-e14501.	1.6	1

#	ARTICLE	IF	CITATIONS
181	Evaluation of Agreement between 64-slice Computed Tomography Angiography and 201-Tl Single Photon Emission Computed Tomography-myocardial Perfusion Imaging in the Diagnosis of Significant Coronary Artery Disease. <i>Journal of the Korean Society of Radiology</i> , 2011, 64, 541.	0.2	0
182	Incidentally Detected Juvenile-Pattern Bone Scintigraphy in a Young Man with Kallmann's Syndrome. <i>Nuclear Medicine and Molecular Imaging</i> , 2014, 48, 247-248.	1.0	0
183	Gastrointestinal stromal tumour with CDKN2A deletions: a report of three cases. <i>Pathology</i> , 2019, 51, 537-539.	0.6	0
184	Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?. <i>Medicine (United States)</i> , 2019, 98, e18437.	1.0	0
185	BCL2 Gene Polymorphism Could Predict the Treatment Outcomes in Patients with De Novo Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 3973-3973.	1.4	0
186	Abstract B38: Troglitazone enhances breast cancer cell 18F-FDG uptake and intracellular lactic acid accumulation through PPAR-independent activation of the MAPK pathway.. , 2011, , .		0
187	A prospective, phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7104-7104.	1.6	0
188	Non Malignant Late Complications After Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT); Korean Experience. <i>Blood</i> , 2012, 120, 4462-4462.	1.4	0
189	Correlation Between Unidentified Bright Objects on Brain Magnetic Resonance Imaging (MRI) and Cerebral Glucose Metabolism in Patients with Neurofibromatosis Type 1. <i>Journal of Genetic Medicine</i> , 2012, 9, 84-88.	0.2	0
190	Natural history of untreated patients who had metastatic biliary tract cancer (BTC) with good performance status (PS).. <i>Journal of Clinical Oncology</i> , 2014, 32, e15106-e15106.	1.6	0
191	A retrospective feasibility analysis of biweekly reduced dose docetaxel in Korean patients with castration-resistant, metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e638-e638.	1.6	0
192	Adjuvant chemotherapy with or without concurrent radiotherapy in stage IB patients with gastric cancer: Subgroup analysis of the adjuvant chemoradiotherapy in stomach tumors (ARTIST) phase III trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 95-95.	1.6	0
193	Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15628-e15628.	1.6	0
194	The clinicopathologic features and treatment of 607 hindgut neuroendocrine tumor (NET) patients at a single institution.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4091-4091.	1.6	0
195	The impact of cetuximab plus AKT- or mTOR- inhibitor in patient-derived colon cancer cell model with RAS wild type and PIK3CA mutation.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15153-e15153.	1.6	0
196	Programmed death (PD)-ligand 1 (L1) expression and mismatch repair (MMR) deficiency across tumor types: Candidates for checkpoint inhibitor based immunotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14622-e14622.	1.6	0
197	The impact of pathologic differentiation (well/ poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15686-e15686.	1.6	0
198	VariantPlex panel to detect genomic aberrations in oncology patients with rare cancer type.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24234-e24234.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Detection of targetable fusions using FusionPlex in oncology patients.. Journal of Clinical Oncology, 2018, 36, e24238-e24238.	1.6	0
200	The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma.. Journal of Clinical Oncology, 2019, 37, 213-213.	1.6	0
201	Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study. Journal of Gynecologic Oncology, 0, 29, .	2.2	0
202	IOX1 impedes host inflammation in imiquimod-triggered psoriasis. Heliyon, 2021, 7, e08433.	3.2	0
203	Primary Subcapsular Reflux as an Etiology of Subcapsular Renal Abscess. Childhood Kidney Diseases, 2021, 25, 133-139.	0.4	0